Sentiment for Pacific Biosciences Of California Inc (NASDAQ:PACB)
Pacific Biosciences Of California Inc (NASDAQ:PACB) institutional sentiment decreased to 1.4 in Q2 2019. Its down -0.45, from 1.85 in 2019Q1. The ratio has worsened, as 70 investment managers increased and started new holdings, while 50 sold and decreased their stakes in Pacific Biosciences Of California Inc. The investment managers in our partner’s database now have: 86.37 million shares, down from 91.20 million shares in 2019Q1. Also, the number of investment managers holding Pacific Biosciences Of California Inc in their top 10 holdings decreased from 1 to 0 for a decrease of 1. Sold All: 18 Reduced: 32 Increased: 50 New Position: 20.
Pacific Biosciences of California, Inc. designs, develops, and makes sequencing systems to resolve genetically complex problems. The company has market cap of $795.05 million. The companyÂ’s single molecule real-time sequencing technology enables single molecule real-time detection of biological processes. It currently has negative earnings. It offers PacBio RS II and Sequel Systems that conducts, monitors, and analyzes biochemical sequencing reactions.
The stock increased 0.49% or $0.03 during the last trading session, reaching $5.14. About 737,495 shares traded. Pacific Biosciences of California, Inc. (NASDAQ:PACB) has risen 52.97% since December 4, 2018 and is uptrending. It has outperformed by 52.97% the S&P500.
Analysts await Pacific Biosciences of California, Inc. (NASDAQ:PACB) to report earnings on February, 10. They expect $-0.16 EPS, up 23.81 % or $0.05 from last year’s $-0.21 per share. After $-0.19 actual EPS reported by Pacific Biosciences of California, Inc. for the previous quarter, Wall Street now forecasts -15.79 % EPS growth.
Havens Advisors Llc holds 2.6% of its portfolio in Pacific Biosciences of California, Inc. for 611,500 shares. Oracle Investment Management Inc owns 1.11 million shares or 1.45% of their US portfolio. Moreover, Highvista Strategies Llc has 1.17% invested in the company for 378,479 shares. The New York-based Water Island Capital Llc has invested 1.09% in the stock. Alpine Associates Management Inc., a New Jersey-based fund reported 6.08 million shares.
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Ratings Coverage
Ratings analysis reveals 50% of Pacific Biosciences’s analysts are positive. Out of 2 Wall Street analysts rating Pacific Biosciences, 1 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $800 while the high is $8. The stock’s average target of $8 is 55.64% above today’s ($5.14) share price. PACB was included in 3 notes of analysts from June 20, 2019. Cantor Fitzgerald maintained Pacific Biosciences of California, Inc. (NASDAQ:PACB) on Thursday, June 20 with “Hold” rating. The stock of Pacific Biosciences of California, Inc. (NASDAQ:PACB) earned “Overweight” rating by Piper Jaffray on Tuesday, October 15.
More notable recent Pacific Biosciences of California, Inc. (NASDAQ:PACB) news were published by: Fool.com which released: “Pump the Brakes on the Illumina and Pacific Biosciences Deal – The Motley Fool” on April 20, 2019, also Fool.com with their article: “Here’s Why Illumina’s $1.2 Billion Acquisition Makes Sense – The Motley Fool” published on November 14, 2018, Finance.Yahoo.com published: “Merger or Not, Pacific Biosciences Needs to Deliver – Yahoo Finance” on September 04, 2019. More interesting news about Pacific Biosciences of California, Inc. (NASDAQ:PACB) were released by: Fool.com and their article: “Better Buy: Illumina vs. Guardant Health – Motley Fool” published on June 11, 2019 as well as Globenewswire.com‘s news article titled: “European Research Initiative Adopts PacBio Sequel II System to Solve Rare Diseases – GlobeNewswire” with publication date: September 05, 2019.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.